What is the lead time for orders?

The average lead time is within 15 workdays for both peak and off-peak seasons.

Foxo4-Dri Peptide for Anti-Aging Raw Powder CAS 2460055-10-9 Foxo4-Dri

Name: Foxo4-Dri Peptide for Anti-Aging Raw Powder CAS 2460055-10-9 Foxo4-Dri
Brand: Hubei Vanz Pharm Co., Ltd.
SKU: 2267468995

Hubei, ChinaHubei Vanz Pharm Co., Ltd.

US$1,200.00-1,800.00

1 gram

Product profile

Customization

Available

Stock

Available

Documents

COA, MSDS

Model NO.

foxo4 dri

Other Products

Available

Product Name

Foxo4 Dri

CAS

2460055-10-9

Appearance

White Powder

package

1g/Tube

Transport Package

Box/Drum

Specification

99%

Trademark

VANZ

Origin

China

HS Code

29225000

Production Capacity

5000kg/Month

Key features

High Purity: 98% purity ensures high quality for anti-aging applications.

GMP Compliance: Manufacturing adheres to Good Manufacturing Practices for safety.

Global Shipping: International delivery available with full regulatory compliance.

R&D Capability: 1000 sqm center with 4 synthesis labs and experienced chemists.

Flexible Packaging: Available in 1g tubes with custom options for bulk orders.

Quality Assurance: Stringent QC standards with COA and MSDS documentation provided.

Company profile

High Repeat Buyers ChoiceYears of Export ExperienceExperienced TeamFast Delivery

Hubei Vanz Pharm Co., Ltd.

Hubei, China

Business Type: Manufacturer/FactoryExport Year: 2013-01-01Nearest Port: shanghaiAverage Response Time: ≤6.61hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB, CFR, CIF, FAS, FCA

AI-Powered supplier vetting

SummaryThe supplier is identified as a factory in Jiayu County, Hubei, producing pharmaceutical intermediates with stated annual productivity of 40 tons. It reports ISO 9001 certification, documented service-assessment, corrective-action, and customer-complaint procedures, and export capability covering multiple regions. Its capabilities include sample-based customization, ODM, and OEM services, while it does not provide 3D software design, has no available SDK, and reported no new products in the past year. The company description states that it has completed R&D for more than 20 APIs and intermediates and operates several laboratories, although other records classify it as not being a professional technical supplier. Overseas warehouses, showrooms, agents or branches, and offline trade-show participation are not available. Customer-specific cases are not explicitly provided.

Supplier typeThe supplier is explicitly identified as a factory, with pharmaceutical intermediates as its stated product and annual productivity of 40 tons. It also holds self-operated import and export rights, indicating manufacturing and direct export capability.

CertificationsThe supplier reports ISO 9001 certification for its management system. This is explicit evidence of holding a recognized quality-management certification.

After-Sales capabilityThe supplier has written and followed procedures for service assessment, corrective and preventive actions, and customer complaints. However, it lacks overseas warehouses, showrooms, agents or branches, and has not participated in offline trade shows, so the evidence supports formal service processes but not broad overseas service coverage.

Production capacityThe supplier is a factory producing pharmaceutical intermediates with stated annual productivity of 40 tons, 6–10 quality-control staff, and stated order fulfillment within 15 working days in both peak and off-peak seasons. These records explicitly support production capability and operational capacity.

Customization capabilityThe supplier provides customization from samples and reports both ODM and OEM services, including services for popular brands. These explicit offerings demonstrate customization and outsourced design/manufacturing capability, although no 3D software design service or SDK is available.